Invivyd Inc
(NAS:IVVD)
$
1.39
0.1 (7.75%)
Market Cap: 165.85 Mil
Enterprise Value: -33.71 Mil
PE Ratio: 0
PB Ratio: 0.93
GF Score: 22/100 - Q3 2023 Invivyd Inc Earnings Call TranscriptNov 09, 2023$1.4 (-7.89%)Earnings
- Invivyd Inc at Guggenheim Securities Inflammation & Immunology Conference TranscriptNov 07, 2023
- Invivyd Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Invivyd Inc Earnings Call TranscriptAug 10, 2023$1.55 (-0.64%)Earnings
- Invivyd Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Invivyd Inc Earnings Call TranscriptMay 11, 2023$1.43 (+0.70%)Earnings
- Invivyd Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Full Year 2022 Invivyd Inc Earnings Call TranscriptMar 23, 2023$1.43 (+0.70%)Earnings
- Q3 2022 Invivyd Inc Earnings Call TranscriptNov 10, 2022$3.56 (+7.55%)Earnings
Invivyd Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 08:00PM GMT
Release Date Price:
$1.15
(-7.26%)
Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright BioConnect Investor Conference in partnership with NASDAQ. I'm Patrick Trucchio. I'm the senior health care analyst at H.C. Wainwright. It's my pleasure to introduce our next speaker, Dave Hering, CEO of Invivyd, a clinical-stage biopharmaceutical company focused on delivering antibody-based therapies to protect vulnerable people from devastating consequences of circulating viral threats, starting with SARS-CoV-2 and then expanding to flu and other high-need indications.
Questions & Answers
Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
So maybe we can start first with just some brief background on Invivyd, including the history of the company.
David Hering
Invivyd, Inc. - CEO & Director
Sure. Thanks, Patrick, and thanks
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)